Outcomes of DA R-EPOCH versus R-CHOP in treating patients diagnosed with Double-Expressor lymphoma

Files

Authors

Phat Duong, Oakland University William Beaumont School of Medicine Student
Ishmael Jaiyesimi, Beaumont Health

Description

Double-expressor lymphoma (DEL) is a subtype of Diffuse Large B-cell lymphoma (DLBCL) that is associated with poor prognosis. The standard treatment for DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). It is hypothesized that the aggressive nature of DEL deserves a more intense regimen such as dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-R-EPOCH). A comparison of outcomes between those two treatments is needed to guide clinical decisions.

Publication Date

5-2023

Keywords

Double-expressor lymphoma

Disciplines

Hematology | Oncology

Recommended Citation

Duong P, Jaiyesimi I. Outcomes of DA R-EPOCH versus R-CHOP in treating patients diagnosed with double-expressor lymphoma. Poster presented at: Oakland University William Beaumont School of Medicine Embark Capstone Colloquium; 2023 May; Rochester Hills, MI.

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2023.